IBDEI0EU ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6488,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,6488,1,1,0)
 ;;=1^Comprehensive
 ;;^UTILITY(U,$J,358.3,6488,1,2,0)
 ;;=2^99215
 ;;^UTILITY(U,$J,358.3,6489,0)
 ;;=99241^^44^404^1
 ;;^UTILITY(U,$J,358.3,6489,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,6489,1,1,0)
 ;;=1^Problem Focused
 ;;^UTILITY(U,$J,358.3,6489,1,2,0)
 ;;=2^99241
 ;;^UTILITY(U,$J,358.3,6490,0)
 ;;=99242^^44^404^2
 ;;^UTILITY(U,$J,358.3,6490,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,6490,1,1,0)
 ;;=1^Expanded Problem Focus
 ;;^UTILITY(U,$J,358.3,6490,1,2,0)
 ;;=2^99242
 ;;^UTILITY(U,$J,358.3,6491,0)
 ;;=99243^^44^404^3
 ;;^UTILITY(U,$J,358.3,6491,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,6491,1,1,0)
 ;;=1^Detailed
 ;;^UTILITY(U,$J,358.3,6491,1,2,0)
 ;;=2^99243
 ;;^UTILITY(U,$J,358.3,6492,0)
 ;;=99244^^44^404^4
 ;;^UTILITY(U,$J,358.3,6492,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,6492,1,1,0)
 ;;=1^Comprehensive, Moderate
 ;;^UTILITY(U,$J,358.3,6492,1,2,0)
 ;;=2^99244
 ;;^UTILITY(U,$J,358.3,6493,0)
 ;;=99245^^44^404^5
 ;;^UTILITY(U,$J,358.3,6493,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,6493,1,1,0)
 ;;=1^Comprehensive, High
 ;;^UTILITY(U,$J,358.3,6493,1,2,0)
 ;;=2^99245
 ;;^UTILITY(U,$J,358.3,6494,0)
 ;;=99024^^44^405^1
 ;;^UTILITY(U,$J,358.3,6494,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,6494,1,1,0)
 ;;=1^Post-Op Follow-up Visit
 ;;^UTILITY(U,$J,358.3,6494,1,2,0)
 ;;=2^99024
 ;;^UTILITY(U,$J,358.3,6495,0)
 ;;=11000^^45^406^1^^^^1
 ;;^UTILITY(U,$J,358.3,6495,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6495,1,2,0)
 ;;=2^11000
 ;;^UTILITY(U,$J,358.3,6495,1,3,0)
 ;;=3^Debride ext eczematous skin,<10%
 ;;^UTILITY(U,$J,358.3,6496,0)
 ;;=11001^^45^406^2^^^^1
 ;;^UTILITY(U,$J,358.3,6496,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6496,1,2,0)
 ;;=2^11001
 ;;^UTILITY(U,$J,358.3,6496,1,3,0)
 ;;=3^Debride ext eczematous skin,Ea 10%
 ;;^UTILITY(U,$J,358.3,6497,0)
 ;;=11042^^45^406^3^^^^1
 ;;^UTILITY(U,$J,358.3,6497,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6497,1,2,0)
 ;;=2^11042
 ;;^UTILITY(U,$J,358.3,6497,1,3,0)
 ;;=3^Debride Subcut (epi/derm);20sq cm or <
 ;;^UTILITY(U,$J,358.3,6498,0)
 ;;=11045^^45^406^4^^^^1
 ;;^UTILITY(U,$J,358.3,6498,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6498,1,2,0)
 ;;=2^11045
 ;;^UTILITY(U,$J,358.3,6498,1,3,0)
 ;;=3^Debride Subcut (epi/derm);Ea Addl 20sq cm
 ;;^UTILITY(U,$J,358.3,6499,0)
 ;;=17000^^45^407^4^^^^1
 ;;^UTILITY(U,$J,358.3,6499,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6499,1,2,0)
 ;;=2^17000
 ;;^UTILITY(U,$J,358.3,6499,1,3,0)
 ;;=3^Destroy 1st Premalignant Lesion
 ;;^UTILITY(U,$J,358.3,6500,0)
 ;;=17004^^45^407^3^^^^1
 ;;^UTILITY(U,$J,358.3,6500,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6500,1,2,0)
 ;;=2^17004
 ;;^UTILITY(U,$J,358.3,6500,1,3,0)
 ;;=3^Destroy 15+ Premalignant Lesions
 ;;^UTILITY(U,$J,358.3,6501,0)
 ;;=17110^^45^407^1^^^^1
 ;;^UTILITY(U,$J,358.3,6501,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6501,1,2,0)
 ;;=2^17110
 ;;^UTILITY(U,$J,358.3,6501,1,3,0)
 ;;=3^Destroy 1-14 Benign Lesions
 ;;^UTILITY(U,$J,358.3,6502,0)
 ;;=17111^^45^407^2^^^^1
 ;;^UTILITY(U,$J,358.3,6502,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6502,1,2,0)
 ;;=2^17111
 ;;^UTILITY(U,$J,358.3,6502,1,3,0)
 ;;=3^Destroy 15+ Benign Lesions
 ;;^UTILITY(U,$J,358.3,6503,0)
 ;;=17003^^45^407^5^^^^1
 ;;^UTILITY(U,$J,358.3,6503,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6503,1,2,0)
 ;;=2^17003
 ;;^UTILITY(U,$J,358.3,6503,1,3,0)
 ;;=3^Destroy 2-14 Premalignant Lesions
 ;;^UTILITY(U,$J,358.3,6504,0)
 ;;=17260^^45^408^1^^^^1
 ;;^UTILITY(U,$J,358.3,6504,1,0)
 ;;=^358.31IA^3^2
